Monday, April 6, 2026 | The Valve Wire

Executive Summary

Today's structural heart landscape centers on the persistent challenge of conduction disturbances after TAVR, new data on heart failure phenotype as a predictor of TAVR outcomes, and a competitive shake-up in the transcatheter tricuspid valve replacement (TTVR) space. A single-center study finds that new-onset persistent left bundle branch block after TAVR impairs early cardiac reverse remodeling — reinforcing why conduction disturbances remain one of the procedure's most consequential complications. Meanwhile, a large national database analysis reveals that patients with reduced ejection fraction fare significantly worse after TAVR than those with preserved EF, raising questions about patient selection in this growing population. On the device front, Vdyne has secured an IDE approval to advance its TTVR system into US pivotal trials, directly challenging Edwards Lifesciences' Evoque in a rapidly evolving tricuspid market.

For the clinical audience: it's a quieter day on the journal front — no top-tier publications (NEJM, JAMA, JACC, Lancet, EHJ) in today's batch — but the themes are anything but trivial. The LBBB-remodeling data from Wang et al. adds granularity to a problem that has dogged the TAVR field since inception: roughly one in four patients develops new conduction disturbances, and the downstream hemodynamic consequences are now becoming clearer. The NRD analysis from Dixit et al. quantifying the HFrEF vs. HFpEF outcome gap in TAVR (n=120,199) deserves attention as we grapple with the expanding indications for TAVR — including the recently published TAVR-UNLOAD results in moderate AS with systolic heart failure. And the Vdyne IDE news signals that the TTVR competitive landscape is intensifying just as the ESC 2025 guidelines have formally endorsed transcatheter tricuspid therapy (Class IIa). Let's unpack it all.

Today's Key Findings

New-onset persistent LBBB after TAVR impairs cardiac reverse remodeling — increased LV dimensions, higher LV mass index, and reduced LVEF at 6 months, with worsening mitral regurgitation after initial improvement (Wang et al., J Cardiothorac Surg)
HFrEF patients undergoing TAVR have significantly worse outcomes than HFpEF — higher in-hospital mortality, complications, and 30-day readmission rates in a 120,199-patient national database analysis (Dixit et al., Curr Probl Cardiol)
Vdyne gains IDE approval for TTVR system — entering the US pivotal trial pathway in direct competition with Edwards' Evoque (MDDI)
Post-TAVR bleeding comparison between apixaban and rivaroxaban in AF patients published (Morel et al., Am J Cardiol) — no abstract available yet, but an increasingly important clinical question
Leaflet modification technique for bicuspid aortic valve enabling larger THV implantation described (Tarantini et al., Am J Cardiol) — a procedural innovation addressing one of TAVR's most challenging anatomies

Aortic Valve (TAVR/TAVI)

New-Onset LBBB Impairs Early Cardiac Reverse Remodeling After TAVR

[NOTABLE] Wang et al. present a single-center retrospective analysis of 101 patients undergoing TAVR for severe aortic stenosis (March 2021–October 2024), of whom 28 (27.7%) developed new-onset persistent LBBB. At 6 months, the LBBB group showed increased LV diameter and LV mass index with reduced LVEF compared to baseline — the opposite of the favorable reverse remodeling expected after aortic stenosis relief. Perhaps most concerning, mitral regurgitation initially improved at 1 month but worsened again by 6 months in the LBBB group, while the no-LBBB group maintained their MR improvement. THV implantation depth was identified as a key modifiable risk factor, and thinner interventricular septum was a predisposing baseline feature.

Editorial perspective: This study is small, single-center, and retrospective — all important caveats. But it adds to a growing body of evidence that new-onset LBBB after TAVR is not benign. The 27.7% LBBB incidence is consistent with published ranges (15–30%), and the finding that initial MR improvement reverses by 6 months has clinical implications: dyssynchronous contraction may progressively distort mitral valve geometry. Worth noting: the 2025 ESC guidelines emphasize that conduction disturbances and pacemaker implantation remain among the most significant TAVR complications, and the recently published data on conduction disturbances even after surgical AVR in BAV patients (PMID referenced in our knowledge base) shows this problem is not unique to TAVR. The question is whether optimizing implant depth — and choosing valve platforms with lower pacemaker/LBBB rates — can meaningfully shift these numbers. The randomized study at Hospital Clinic of Barcelona comparing conduction system pacing vs. RV pacing post-TAVI (NCT06197503) is directly relevant here.

HFrEF vs. HFpEF Outcomes in TAVR: A 120,000-Patient Analysis

[NOTABLE] Dixit et al. analyzed 120,199 patients undergoing TAVR at metropolitan teaching hospitals (NRD 2016–2022), stratified by HFrEF (16.25%) and HFpEF (83.75%). After adjusting for baseline comorbidities, HFrEF was associated with higher rates of virtually every in-hospital complication — cardiogenic shock, mechanical circulatory support, ECMO, CPR, acute kidney injury, acute MI, mechanical ventilation — as well as higher in-hospital mortality. The 30-day all-cause readmission rate was also significantly higher in HFrEF (11.29% vs. 9.74%; HR 1.14, 95% CI 1.13–1.16).

Editorial perspective: These findings are not surprising — HFrEF patients have lower hemodynamic reserve and more comorbidities — but the scale of this analysis lends it considerable weight. The timing is also relevant: the recently published TAVR-UNLOAD trial (JACC Cardiovasc Interv, referenced in our knowledge base) tested TAVR in patients with moderate AS and HFrEF and failed to meet its primary hierarchical composite endpoint, though QoL improved. This NRD analysis reinforces that HFrEF patients represent a fundamentally higher-risk population for TAVR, regardless of AS severity. As TAVR indications potentially expand to include moderate AS with heart failure, the field must reckon with this risk gradient. Both the 2020 ACC/AHA and 2025 ESC guidelines emphasize shared decision-making and life expectancy considerations — data like these should factor prominently into those discussions.

Post-TAVR Bleeding: Apixaban vs. Rivaroxaban in AF Patients

Morel et al. (American Journal of Cardiology) have published a comparison of bleeding outcomes in atrial fibrillation patients treated with apixaban versus rivaroxaban after TAVR. No abstract is yet available, but this addresses a critically important gap: the 2025 ESC guidelines recommend anticoagulation for AF after TAVR but offer limited guidance on DOAC selection. Post-TAVR bleeding remains one of the leading causes of morbidity and readmission, and real-world data comparing specific DOACs in this population are sparse. We will update when the full text becomes available.

Leaflet Modification for Bicuspid Aortic Valve Tricuspidalization

Tarantini et al. (American Journal of Cardiology) describe a leaflet modification technique for bicuspid aortic valve (BAV) that enables tricuspidalization and implantation of larger transcatheter heart valves. No abstract is available yet, but this procedural innovation addresses a core challenge in BAV TAVR: the asymmetric, often heavily calcified raphe creates elliptical geometry that limits THV sizing and increases paravalvular leak risk. Both the ACC/AHA 2020 (Class IIb) and ESC 2025 (Class IIb) guidelines maintain that BAV remains primarily surgical territory — BAV patients were excluded from virtually all TAVR vs. SAVR RCTs. Techniques that improve BAV TAVR feasibility are welcome, but it's worth emphasizing that NOTION 2's BAV subset showed a numerically higher event rate with TAVI (HR 3.8, P=0.07). We await the full text to assess the technical details and any outcomes data.

TAVR Market Segmentation Report

openPR.com reports on a new market analysis covering TAVR segmentation, major trends, and competitive landscape. The report underscores the continued global growth trajectory for TAVR, driven by expanding indications into lower-risk populations and the ESC 2025 guideline shift lowering the TAVI-preferred age threshold to ≥70 years. Edwards Lifesciences and Medtronic continue to dominate, with emerging competition from Meril Life Sciences (Myval), JenaValve, and others.

Tricuspid Valve (TriClip, TTVR)

Vdyne Gains IDE Approval for Transcatheter Tricuspid Valve Replacement

[NOTABLE] Medical Device and Diagnostic Industry reports that Vdyne has received an Investigational Device Exemption (IDE) from the FDA, clearing the path for its transcatheter tricuspid valve replacement (TTVR) system to enter pivotal US clinical trials. This positions Vdyne as a direct competitor to Edwards Lifesciences' Evoque TTVR system, which is currently being studied in the landmark TRISCEND II trial (NCT04482062, 864 patients, active but not recruiting).

Editorial perspective: The tricuspid space has undergone a remarkable transformation. The 2020 ACC/AHA guidelines did not address transcatheter TR therapy at all. Five years later, the ESC 2025 guidelines recommend transcatheter TV treatment as Class IIa (LOE A) for high-risk symptomatic severe TR despite optimal medical therapy — based on TRILUMINATE Pivotal, Tri.Fr, and TRISCEND II data. Vdyne's IDE approval means the TTVR landscape is no longer a two-horse race (Edwards Evoque vs. Abbott TriClip repair); it's becoming a multi-modality competition between repair and replacement approaches. The key unanswered question remains whether full tricuspid valve replacement offers durable advantages over edge-to-edge repair, and at what complication cost — TRISCEND II showed symptom/QoL superiority but higher bleeding and pacemaker rates. Vdyne's early feasibility study (VISTA-US, NCT05848284) is currently recruiting 30 patients. Competition is good for the field, but we should be cautious about enthusiasm outpacing evidence — a pattern well-documented in transcatheter valve history.

Device & Technology

Beyond the Vdyne IDE approval covered above, today's trial updates reveal continued activity across multiple device platforms:

MitraFix® Transcatheter Mitral Valve System (NCT07501234) — a first-in-human safety and feasibility study enrolling 5 patients is now recruiting, sponsored by Mitrassist Lifesciences. Another entrant in the crowded TMVR space.
SAPIEN 3 Ultra RESILIA Valve long-term evaluation (NCT06953206) — a 500-patient prospective registry for Edwards' latest TAVR platform is not yet recruiting. RESILIA tissue treatment is Edwards' durability play, and long-term data will be critical for supporting TAVR use in younger patients.
JenaValve ALIGN-AR LVAD Registry (NCT06594705) — recruiting 50 patients to evaluate the Trilogy system in the niche but important population of LVAD patients with aortic regurgitation. The ESC 2025 guidelines rate TAVI for AR as Class IIb for inoperable patients — JenaValve's locator-based technology is uniquely suited for native AR.

Financial Analysis

The structural heart sector finds itself in a turbulent macro environment as we enter the second quarter of 2026. Among the four major publicly traded players, the divergence in 6-month performance is striking: Edwards Lifesciences is up modestly (+5.2%), Anteris Technologies has rallied (+16.2%), while Medtronic (-10.0%) and Abbott (-22.8%) have pulled back meaningfully. Boston Scientific has been hit hardest, down 35.5% over six months from its highs — though it retains a "strong buy" consensus with significant upside to analyst targets.

The upcoming earnings season is the key near-term catalyst. Abbott reports April 16 (EPS est. $1.15, revenue est. $11.0B) and Edwards reports April 22 (EPS est. $0.73, revenue est. $1.60B) — both will offer critical reads on TAVR procedure volumes, TriClip/PASCAL adoption, and geographic trends. Boston Scientific also reports April 22 (EPS est. $0.79, revenue est. $5.18B). Medtronic's next report isn't until May 20, but investors will be watching for commentary on Evolut FX+ uptake and Intrepid TMVR progress.

The institutional positioning data point — Nvwm LLC disclosed $1.46M in Edwards holdings — is routine but reflects ongoing institutional confidence in Edwards' structural heart franchise ahead of earnings. The broader question for the sector is whether the ESC 2025 guideline expansions (TAVI at ≥70, TEER Class I for SMR, transcatheter tricuspid Class IIa) will translate into measurable procedure volume growth in the coming quarters, or whether reimbursement and real-world adoption will lag the guidelines.

Valve Industry Stocks

6-Month Valve Industry Stock Performance

Edwards Lifesciences (EW)

Close: $81.05 | Daily Change: -$0.21 (-0.26%)
6-Month Performance: +$3.98 (+5.16%)
Market Cap: $47.1B | P/E (trailing): 44.78 | P/E (forward): 24.48 | Beta: 0.94
52-Week Range: $65.94 - $87.89
Analyst Consensus Target: $96.93 (range: $84 - $110, 27 analysts) — Buy
Next Earnings: April 22, 2026 (EPS est. $0.73, Revenue est. $1.60B)

Edwards trades at a premium valuation reflecting its dominant TAVR franchise and expanding TEER portfolio (PASCAL). The stock has outperformed the broader medtech sell-off, up 5% over six months while peers have struggled. The April 22 earnings call will be closely watched for TAVR volume trends in the US and Europe — particularly whether the ESC 2025 guideline shift to TAVI-preferred at ≥70 is accelerating European adoption. The SAPIEN 3 Ultra RESILIA long-term registry and Evoque TTVR program are key pipeline drivers. The Vdyne IDE approval introduces new competitive pressure in the tricuspid replacement space.

Medtronic (MDT)

Close: $86.63 | Daily Change: +$0.57 (+0.66%)
6-Month Performance: -$9.57 (-9.95%)
Market Cap: $111.2B | P/E (trailing): 24.20 | P/E (forward): 14.29 | Beta: 0.76
52-Week Range: $79.55 - $106.33
Analyst Consensus Target: $110.60 (range: $91 - $125, 25 analysts) — Buy
Next Earnings: May 20, 2026 (EPS est. $1.54, Revenue est. $9.65B)

Medtronic has pulled back nearly 10% over six months, underperforming despite a strong structural heart pipeline that includes the Evolut FX+ TAVR platform and the Intrepid TMVR system (the latter enrolling in the pivotal APOLLO trial with 1,056-patient target). The attractive forward P/E of 14.3 reflects the diversified conglomerate structure, but structural heart investors are focused on whether Medtronic can close the TAVR market share gap with Edwards. The Evolut Low Risk long-term follow-up data remain critical for positioning in the sub-70 patient debate.

Abbott (ABT)

Close: $102.87 | Daily Change: +$0.49 (+0.48%)
6-Month Performance: -$30.45 (-22.84%)
Market Cap: $178.8B | P/E (trailing): 27.65 | P/E (forward): 16.85 | Beta: 0.78
52-Week Range: $100.88 - $139.06
Analyst Consensus Target: $132.28 (range: $113 - $158, 25 analysts) — Buy
Next Earnings: April 16, 2026 (EPS est. $1.15, Revenue est. $11.0B)

Abbott has been the worst performer among the major diversified medtech names, down nearly 23% over six months and trading at its 52-week low. The structural heart business — anchored by MitraClip/TriClip — faces a critical inflection point: the ESC 2025 upgrade of TEER for ventricular SMR to Class I (LOE A) should be a tailwind, and the TriClip Japan Post-Approval Study (NCT07509658) is now recruiting, signaling geographic expansion. The April 16 earnings call will be the first major medtech readout of the quarter. REPAIR-MR results comparing MitraClip to surgery for primary MR remain a key catalyst. The current price represents 29% upside to analyst consensus — the question is whether broader macro headwinds or company-specific issues are driving the decline.

Boston Scientific (BSX)

Close: $62.82 | Daily Change: +$0.82 (+1.32%)
6-Month Performance: -$34.50 (-35.45%)
Market Cap: $93.4B | P/E (trailing): 32.38 | P/E (forward): 16.07 | Beta: 0.78
52-Week Range: $61.25 - $109.50
Analyst Consensus Target: $100.81 (range: $83 - $124, 32 analysts) — Strong Buy
Next Earnings: April 22, 2026 (EPS est. $0.79, Revenue est. $5.18B)

Boston Scientific has been hammered, losing over a third of its value in six months despite maintaining a "strong buy" consensus from 32 analysts with 61% upside to target. While BSX's structural heart exposure is more limited than Edwards or Abbott (primarily the ACURATE neo2 TAVR platform in Europe and the WATCHMAN LAAO franchise), the company's overall cardiovascular portfolio makes it a barometer for the sector. The steep sell-off suggests broader market risk-off sentiment rather than structural-heart-specific concerns. Earnings on April 22 will be pivotal.

Anteris Technologies (AVR.AX)

Close: A$7.55 | Daily Change: -A$0.33 (-4.19%)
6-Month Performance: +A$1.05 (+16.15%)
Market Cap: A$0.8B | P/E (forward): -3.46 (pre-revenue) | Beta: 0.55
52-Week Range: A$4.26 - A$9.79
Analyst Target: A$13.00 (1 analyst)

Anteris continues its volatile trajectory as a pre-revenue structural heart company developing the DurAVR single-piece TAVR valve with ADAPT tissue technology. The stock is up 16% over six months but pulled back 4.2% on the day, reflecting the typical volatility of small-cap medtech. The investment thesis rests entirely on whether DurAVR's biomimetic design and tissue treatment can demonstrate superior hemodynamics and durability in clinical trials. This is speculative territory — the company has no approved products and faces a long regulatory pathway.

Private companies to watch: JenaValve Technology (Trilogy system for AR and AS, ALIGN-AR LVAD Registry recruiting), Meril Life Sciences (Myval THV, demonstrated noninferiority in LANDMARK trial), and J Valve Technology remain private and therefore outside public market coverage. JenaValve's aortic regurgitation focus fills a unique niche — the ESC 2025 guidelines added TAVI for AR as Class IIb for inoperable patients, creating a new addressable market.

Market Outlook: The structural heart sector faces a paradox heading into earnings season: the clinical and guideline evidence base has never been stronger (ESC 2025 expansions across aortic, mitral, and tricuspid valves), yet stock prices are under significant pressure from macro headwinds. The April earnings cycle — Abbott (4/16), Edwards (4/22), and Boston Scientific (4/22) — will reveal whether the guideline tailwinds are translating into procedure volume growth. Investors should watch for commentary on European TAVR volumes post-ESC guidelines, MitraClip/TriClip adoption trends, and pipeline milestones for TMVR and TTVR programs.

Clinical Trial Updates

Aortic Valve Trials

[LANDMARK] Evolut Low Risk Long-Term Follow-Up (NCT02701283) — Status: Active, not recruiting | Enrollment: 2,223 | Sponsor: Medtronic Cardiovascular | The pivotal low-risk TAVR trial continues long-term follow-up, with data critical for establishing TAVR durability beyond 5 years and informing the SAVR vs. TAVI debate in patients <70 years. Both ACC/AHA and ESC guidelines reference this trial in their recommendations.
SAPIEN 3 Ultra RESILIA Long-Term Evaluation (NCT06953206) — Status: Not yet recruiting | Enrollment: 500 | Sponsor: Institut für Pharmakologie und Präventive Medizin | Prospective registry evaluating Edwards' latest-generation TAVR platform with RESILIA tissue treatment, designed to address durability concerns.
Pressure-Based Evaluation of Disease Improvement in TAVI (PReDICT) (NCT07509554) — Status: Not yet recruiting | Enrollment: 100 | Sponsor: Istanbul Mehmet Akif Ersoy Hospital | Hemodynamic assessment study post-TAVR.
Conduction System vs. RV Pacing Post-TAVI (NCT06197503) — Status: Recruiting | Enrollment: 48 | Sponsor: Hospital Clinic of Barcelona | Randomized comparison directly relevant to today's LBBB remodeling data.
Microvascular Function in TAVI Patients (NCT05326126) — Status: Completed | Enrollment: 75 | Evaluating coronary microvascular function and myocardial fibrosis association in severe AS patients undergoing TAVI.
TAP Block in TAVI (NCT06762288) — Status: Completed | Enrollment: 50 | Anesthesia optimization study for transfemoral TAVI procedures.
EASE-IT CT Registry (NCT05750173) — Status: Completed | Enrollment: 150 | Pre-procedural CT pathway optimization for TAVR planning.
NHLBI-Emory Advanced Cardiac CT Reconstruction (NCT05372627) — Status: Not yet recruiting | Enrollment: 1,000 | Advanced CT imaging research relevant to structural heart planning.

Mitral Repair Trials

[LANDMARK] REPAIR-MR — MitraClip vs. Surgery for Primary MR (NCT04198870) — Status: Active, not recruiting | Enrollment: 500 | Sponsor: Abbott Medical Devices | This is the pivotal head-to-head trial comparing TEER to surgical MV repair for primary MR. Results will directly inform whether TEER can challenge surgery's Class I dominance in degenerative MR. Both current guidelines rate surgery as first-line for primary MR in operable patients.
[LANDMARK] PRIMATY — MitraClip vs. Medical Therapy for Secondary MR (NCT05051033) — Status: Recruiting | Enrollment: 450 | Sponsor: Annetine Gelijns | An NHLBI-funded, investigator-initiated trial testing TEER vs. surgical MV repair for secondary MR — a different question than COAPT, which compared TEER to medical therapy alone. Critical for defining whether surgery has a role in ventricular SMR beyond COAPT criteria.
[LANDMARK] COAPT Long-Term Follow-Up (NCT03706833) — Status: Active, not recruiting | Enrollment: 1,247 | Sponsor: Edwards Lifesciences | Now studying PASCAL alongside MitraClip in the COAPT extension. The 5-year data supported the ESC 2025 upgrade of TEER for ventricular SMR to Class I. Longer follow-up will determine durability of benefit.
Edwards PASCAL Pivotal Trial (NCT04097145) — Status: Recruiting | Enrollment: 870 | Sponsor: Edwards Lifesciences | Pivotal trial for the PASCAL TEER system across multiple MR etiologies, evaluating against both optimal medical therapy and the PASCAL system itself in different arms. Updated March 31.

Mitral Replacement Trials

[LANDMARK] Intrepid TMVR (APOLLO) (NCT03242642) — Status: Recruiting | Enrollment: 1,056 | Sponsor: Medtronic Cardiovascular | The largest TMVR pivotal trial, evaluating Medtronic's Intrepid system. Updated March 31. TMVR represents the next frontier in transcatheter mitral therapy, but the technology is far less mature than TEER.
MitraFix® Transcatheter Mitral Valve System — First-in-Human (NCT07501234) — Status: Recruiting | Enrollment: 5 | Sponsor: Mitrassist Lifesciences | Very early-stage FIH study for a novel TMVR platform. Updated March 30.

Tricuspid Repair Trials

[LANDMARK] TRILUMINATE Pivotal — TriClip for TR (NCT03904147) — Status: Active, not recruiting | Enrollment: 572 | Sponsor: Abbott Medical Devices | The pivotal trial that, along with Tri.Fr, established transcatheter TR repair as a guideline-supported therapy (ESC 2025 Class IIa). Longer-term outcomes will determine durability of benefit.
TriClip Japan Post-Approval Study (NCT07509658) — Status: Recruiting (NEW) | Enrollment: 250 | Sponsor: Abbott Medical Devices | Post-approval study supporting TriClip's Japanese market launch. Updated April 3. Geographic expansion of transcatheter tricuspid therapy continues.

Tricuspid Replacement Trials

[LANDMARK] TRISCEND II — Evoque Tricuspid Replacement (NCT04482062) — Status: Active, not recruiting | Enrollment: 864 | Sponsor: Edwards Lifesciences | The pivotal TTVR trial referenced in ESC 2025 guidelines. Demonstrated symptom/QoL superiority over medical therapy but with higher procedural complication rates. Updated February 27.
VISTA-US — Vdyne TTVR System (NCT05848284) — Status: Recruiting | Enrollment: 30 | Sponsor: VDyne, Inc. | Early feasibility study for the Vdyne TTVR system, which just received IDE approval (see news coverage above). Updated March 31.

Aortic Regurgitation

JenaValve ALIGN-AR LVAD Registry (NCT06594705) — Status: Recruiting | Enrollment: 50 | Sponsor: JenaValve Technology | Evaluating the Trilogy system in LVAD patients with AR — a niche but clinically important population. Updated April 1.

Closing Thought

Today's data on LBBB-mediated remodeling and HFrEF outcomes after TAVR serve as a reminder that expanding transcatheter indications requires rigorous attention to patient selection and complication mitigation. As we await the approaching earnings season — Abbott on April 16, Edwards and Boston Scientific on April 22 — the structural heart field sits at a fascinating inflection point: the strongest guideline endorsements in history coinciding with significant market uncertainty. In the tricuspid space, Vdyne's IDE marks the beginning of real competition in TTVR. The evidence is moving fast. The question, as always, is whether it's moving fast enough to keep up with the devices.

— E. Nolan Beckett, The Valve Wire